Cognitive assessment in patients with myotonic dystrophy type 2

被引:4
|
作者
Peric, Stojan [1 ,2 ,6 ]
Gunjic, Ilija [2 ]
Delic, Neda [2 ]
Tamas, Olivera Stojiljkovic [1 ,2 ]
Salak-Djokic, Biljana [1 ]
Pesovic, Jovan [3 ]
Djordjevic, Ivana Petrovic [2 ,4 ]
Ivanovic, Vukan [1 ]
Savic-Pavicevic, Dusanka [3 ]
Meola, Giovanni [5 ]
Rakocevic-Stojanovic, Vidosava [1 ,2 ]
机构
[1] Univ Clin Ctr Serbia, Neurol Clin, Dr Subot St 6, Belgrade 11000, Serbia
[2] Univ Belgrade, Fac Med, Dr Subot St 8, Belgrade 11000, Serbia
[3] Univ Belgrade, Fac Biol, Studentski Trg 16, Belgrade, Serbia
[4] Univ Clin Ctr Serbia, Cardiol Clin, Pasterova 2, Belgrade 11000, Serbia
[5] Univ Milan, Dept Neurorehabil Sci, Dept Biomed Sci Hlth, Casa Cura Policlin, Via Dezza 48, I-20144 Milan, Italy
[6] Univ Belgrade, Univ Clin Ctr Serbia, Fac Med, Neurol Clin, 6 Dr Subot St, Belgrade 11000, Serbia
关键词
Myotonic dystrophy type 2; Neuropsychological testing; Cognitive impairment; Activities of daily living; CEREBRAL-BLOOD-FLOW; INVOLVEMENT; IMPAIRMENT; METABOLISM;
D O I
10.1016/j.nmd.2022.06.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Myotonic dystrophy type 2 (DM2) is an autosomal dominant multisystemic disorder. Previous studies conducted on small cohorts of DM2 patients indicated presence of a cognitive dysfunction. We aimed to assess cognitive functions in a larger cohort of Serbian DM2 patients using an extensive battery of neuropsychological tests. The study included 76 patients with a genetically confirmed DM2, 68 of whom had all tests for different cognitive domains performed. Patients underwent clinical and neuropsychological testing, including cognitive screening and assessment of general intellectual level, attention, executive and visuospatial abilities, memory, and language functions. Only 6% of patients achieved a below-average score on the general intellectual level test. Cognitive screening tests indicated presence of cognitive deficits in 5.5% of patients according to the Mini Mental State Examination test and 25.8% according to the Addenbrooke's Cognitive Examination Revised test. Twenty-four (35.3%) patients had a cognitive impairment (being two standard deviations out of norm in at least two cognitive domains). Around one quarter of DM2 patients had a significant cognitive impairment that interfered with their everyday functioning. Patients with significant cognitive impairment were older at testing and at disease onset, less educated, and had more severe muscle weakness.(c) 2022 The Authors. Published by Elsevier B.V.This is an open access article under the CC BY-NC-ND license( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:743 / 748
页数:6
相关论文
共 50 条
  • [21] Musculoskeletal pain in patients with myotonic dystrophy type 2
    George, A
    Schneider-Gold, C
    Zier, S
    Reiners, K
    Sommer, C
    ARCHIVES OF NEUROLOGY, 2004, 61 (12) : 1938 - 1942
  • [22] Myotonic dystrophy type 2/proximal myotonic myopathy
    Wieser, T
    Müller, T
    NERVENHEILKUNDE, 2004, 23 (08) : 447 - +
  • [23] Dyspnea assessment in myotonic dystrophy type 1
    Delbarrea, B.
    Rapin, A.
    Boyer, F. C.
    Thierry, A.
    Perotin, J. M.
    Dury, S.
    Dumazet, A.
    Hagenburg, J.
    Perdu, D.
    Deslee, G.
    Launois, C.
    NEUROMUSCULAR DISORDERS, 2023, 33 (02) : 187 - 195
  • [24] Myotonic dystrophy type 2 and related myotonic disorders
    Giovanni Meola
    Richard T. Moxley
    Journal of Neurology, 2004, 251 : 1173 - 1182
  • [25] Characterizing cognitive-motor impairments in patients with myotonic dystrophy type 1
    Filli, Linard
    Schwegler, Selina
    Meyer, Christian
    Killeen, Tim
    Easthope, Christopher S.
    Broicher, Sarah D.
    Curt, Armin
    Zorner, Bjorn
    Bolliger, Marc
    Jung, Hans H.
    Petersen, Jens A.
    NEUROMUSCULAR DISORDERS, 2020, 30 (06) : 510 - 520
  • [26] Myotonic dystrophy type 2 and related myotonic disorders
    Meola, G
    Moxley, RT
    JOURNAL OF NEUROLOGY, 2004, 251 (10) : 1173 - 1182
  • [27] Current Treatment Options for Patients with Myotonic Dystrophy Type 2
    Montagnese, Federica
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2021, 23 (09)
  • [28] Muscle pathology in 57 patients with myotonic dystrophy type 2
    Schoser, BGH
    Schneider-Gold, C
    Kress, W
    Goebel, HH
    Reilich, P
    Koch, MC
    Pongratz, DE
    Toyka, KV
    Lochmüller, H
    Ricker, K
    MUSCLE & NERVE, 2004, 29 (02) : 275 - 281
  • [29] Commentary: Autoimmune diseases in patients with myotonic dystrophy type 2
    Damen, Manon J.
    den Broeder, Alfons A.
    Voermans, Nicol C.
    Tieleman, Alide A.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [30] Myotonic dystrophy type 2: clinical characteristics of 23 patients
    Lusakowska, A.
    Sulek, A.
    Krysa, W.
    Nadaj-Pakleza, A.
    Szmidt-Salkowska, E.
    Pruszczyk, P.
    Kaminska, A. M.
    JOURNAL OF NEUROLOGY, 2007, 254 : 153 - 153